Position in NAMS
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$9,240,244
+$512,590 QoQ
Shares Held
272,654
0.0% QoQ
Ownership
0.228%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#52
of 198 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NAMS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SEB Asset Management AB holds $515,211,470 across 33 Biotechnology names. NAMS ranks #22 (1.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
138,097 | $68,596,922 | |
| 2 | INCY |
Incyte Corp
|
558,467 | $63,307,819 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
209,963 | $25,737,264 | |
| 4 | RPRX |
Royalty Pharma plc
|
443,035 | $24,840,972 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
412,150 | $23,583,223 | |
| 6 | BNTX |
BioNTech SE
|
245,068 | $22,803,577 | |
| 7 | IBRX |
ImmunityBio, Inc.
|
2,447,150 | $21,424,798 | |
| 8 | ORKA |
Oruka Therapeutics, Inc.
|
196,753 | $18,724,983 |
All Filings in NAMS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9,240,244 | 272,654 | Shares | Sole | 2026-08-04 | |
| 2026-03-31 | $8,727,654 | 272,654 | Shares | Sole | 2026-05-07 | |
| No filing history on record for this holder in this stock. | ||||||